Founded with a mission to revolutionize ophthalmic care, i-Lumen Scientific focuses on developing noninvasive therapies for dry age-related macular degeneration (dAMD). The company aims to address the significant unmet needs in ophthalmology by improving eyesight in patients affected by this condition. Their flagship product, the i-LUMEN™ system, is a software-based medical device designed to deliver innovative, non-invasive treatment, potentially transforming the standard of care for dAMD patients.nni-Lumen Scientific has garnered attention from notable figures in the biotech and ophthalmology sectors, securing investments from key industry players.
The company's pioneering approach has led to significant advancements in noninvasive retinal therapy, positioning it as a leader in the field. With its groundbreaking technology, i-Lumen Scientific is making a substantial impact on the lives of individuals suffering from dAMD, offering hope and improved vision through cutting-edge solutions.
